Corcept Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Corcept Therapeutics de 41% y 22.6% respectivamente, mientras que el BPA crecerá en un 38.3% al año.

Información clave

41.0%

Tasa de crecimiento de los beneficios

38.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.8%
Tasa de crecimiento de los ingresos	22.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CORT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,042	395	510	318	3
12/31/2025	810	224	278	232	5
12/31/2024	691	155	198	198	5
9/30/2024	629	140	143	145	N/A
6/30/2024	570	125	123	124	N/A
3/31/2024	524	117	125	125	N/A
12/31/2023	482	105	127	127	N/A
9/30/2023	450	91	154	155	N/A
6/30/2023	428	94	135	135	N/A
3/31/2023	414	94	111	111	N/A
12/31/2022	402	101	120	120	N/A
9/30/2022	398	117	136	136	N/A
6/30/2022	392	113	151	151	N/A
3/31/2022	380	112	177	178	N/A
12/31/2021	366	113	167	168	N/A
9/30/2021	353	106	153	154	N/A
6/30/2021	343	98	134	135	N/A
3/31/2021	340	99	143	144	N/A
12/31/2020	354	106	151	152	N/A
9/30/2020	356	109	164	165	N/A
6/30/2020	351	114	173	173	N/A
3/31/2020	335	106	145	146	N/A
12/31/2019	306	94	135	136	N/A
9/30/2019	285	87	108	109	N/A
6/30/2019	268	78	114	115	N/A
3/31/2019	258	76	104	105	N/A
12/31/2018	251	75	115	116	N/A
9/30/2018	238	152	119	119	N/A
6/30/2018	216	148	N/A	85	N/A
3/31/2018	189	142	N/A	86	N/A
12/31/2017	159	129	N/A	61	N/A
9/30/2017	130	35	N/A	41	N/A
6/30/2017	109	24	N/A	39	N/A
3/31/2017	93	13	N/A	25	N/A
12/31/2016	81	8	N/A	18	N/A
9/30/2016	72	5	N/A	18	N/A
6/30/2016	64	1	N/A	10	N/A
3/31/2016	56	-2	N/A	8	N/A
12/31/2015	50	-6	N/A	3	N/A
9/30/2015	44	-11	N/A	-2	N/A
6/30/2015	38	-17	N/A	-9	N/A
3/31/2015	32	-22	N/A	-18	N/A
12/31/2014	27	-31	N/A	-27	N/A
9/30/2014	22	-39	N/A	-34	N/A
6/30/2014	17	-44	N/A	-36	N/A
3/31/2014	13	-48	N/A	-37	N/A
12/31/2013	10	-46	N/A	-37	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (41% al año) de CORT es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (41% al año) de CORT crezcan más rápidamente que el mercado US (15.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de CORT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (22.6% al año) de CORT crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (22.6% al año) de CORT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CORT se prevé que sea elevada dentro de 3 años.

Corcept Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 21%

Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024

Price target increased by 14% to US$74.64

Consensus EPS estimates increase by 20%

Price target increased by 20% to US$59.60

Price target increased by 14% to US$49.70

Recent updates

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 21%

Chief Development Officer notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024

Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024

Price target increased by 14% to US$74.64

Chief Business Officer & Secretary notifies of intention to sell stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Investor sentiment improves as stock rises 19%

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Chief Development Officer notifies of intention to sell stock

Consensus EPS estimates increase by 20%

Co-Founder exercised options and sold US$9.2m worth of stock

Price target increased by 20% to US$59.60

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024

Chief Business Officer & Secretary notifies of intention to sell stock

Price target increased by 14% to US$49.70

Chief Development Officer notifies of intention to sell stock

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome)

President of Endocrinology notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial

Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024

Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

New minor risk - Shareholder dilution

Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024

Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Chief Accounting Officer notifies of intention to sell stock

Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome

President of Endocrinology notifies of intention to sell stock

President of Endocrinology exercised options and sold US$364k worth of stock

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

President of Endocrinology notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial

Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024

Price target increased by 11% to US$39.60

New minor risk - Share price stability

Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology

Chief Scientific Officer exercised options and sold US$728k worth of stock

Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024

Chief Development Officer notifies of intention to sell stock

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

President of Corcept Endocrinology notifies of intention to sell stock

Consensus EPS estimates increase by 13%

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Price target increased by 8.1% to US$36.83

President of Corcept Endocrinology notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis

Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023

President of Corcept Endocrinology exercised options and sold US$452k worth of stock

President of Corcept Endocrinology notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

President of Corcept Endocrinology notifies of intention to sell stock

Chief Scientific Officer recently sold US$632k worth of stock

Chief Scientific Officer exercised options and sold US$811k worth of stock

Investor sentiment improves as stock rises 22%

Price target increased by 7.3% to US$32.92

Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023

Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Chief Accounting Officer notifies of intention to sell stock